What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

http://www.AllianceforClinicalTrialsinOncology.org/

Alliance for Clinical Trials in Oncology, Alliance for Clinical Trials in Oncology, Alliance Operations, 311 S. Wacker Drive, Suite 2650, Boston, MA (2026)

Q: What is the address?

Alliance For Clinical Trials In Oncology, Alliance Operations, 311 S. Wacker Drive, Suite 2650

04/22/2026

🚨 Now Enrolling!
Sascha Tuchman, MD, of UNC Lineberger leads Alliance A062102, a new study for people living with multiple myeloma. This trial is looking at whether a daily pill called iberdomide can help keep myeloma under control longer compared with the usual approach of simply monitoring the disease after initial treatment.
What the study is trying to learn:
➡️ Can iberdomide help people stay in remission longer?
➡️ Could it improve overall survival?
➡️ How does it compare to regular follow up without additional treatment?
Why this matters:
Multiple myeloma often comes back over time, even after successful treatment. Finding maintenance options that are effective and easy to take could make a meaningful difference for patients and families.
Alliance A062102 is now enrolling participants who want to help advance future care for myeloma.
Learn more about the study: https://bit.ly/Alliance-A062102
https://bit.ly/Alliance-A062102

04/21/2026

➡️ Trial Tuesday!
Newly activated Alliance A072301 offers fresh possibilities for people with IDH mutated grade 3 astrocytoma, a type of brain tumor. Led by the Dana-Farber’s Dr. Ugonma Chukwueke, this study explores whether adding the targeted therapy vorasidenib to standard treatment can improve outcomes after radiation therapy.
🧠 Why it matters: Vorasidenib blocks proteins produced by mutated IDH1/IDH2 genes, potentially helping slow tumor growth.
🔗 Learn more: https://bit.ly/Brain2026

04/21/2026

New findings of an Alliance Foundation Trials study show combining immunotherapy and chemotherapy before surgery improves outcomes for some patients with locally advanced non-small cell lung cancer, according to the results of AFT-46/CHIO3 published in Lung Cancer.

“These results are exciting because they give us a new, successful blueprint for treating stage III lung cancer that has traditionally been difficult to manage,” said Linda W. Martin, MD, MPH, lead investigator, primary author of the study and a Professor of Thoracic Surgery at the University of Virginia. “This study shows that combining chemotherapy with immunotherapy can help more patients with lung cancer involving mediastinal nodes undergo complete cancer resection, improving their long term health.”

“To our knowledge, this is the first trial specifically focused lymph node clearance in this population, and the results look very promising,” said David Kozono, MD, PhD, Director of the Alliance Foundation, and Director of Thoracic Radiation Oncology at Mass General Brigham Cancer Center. “The high rates of lymph node clearance and successful surgical resection confirm this approach as an important option for patients with this stage of lung cancer.”

04/21/2026

🔬 We were proud of the strong Alliance research at the 2026 AACR Annual Meeting, showcasing work that spans clinical trial methodology, cancer biology, and patient outcomes.
🔹 Advancing early‑phase trial design
Dr. Sumithra Mandrekar leads a methods workshop on model‑assisted designs for early‑phase clinical trials, highlighting how thoughtful statistical approaches can improve efficiency, rigor, and ethical standards—critical foundations for successful translational research.
🔹 New insights into AML disparities and survival
In work led by Dr. Ann‑Kathrin Eisfeld, researchers identified novel Rho‑GTPase regulatory protein (ARHG) gene family mutations that are more frequent in AML patients from diverse ancestral backgrounds and are associated with poorer survival. These findings help address gaps created by historically homogeneous genomic datasets and point toward a newly recognized, clinically relevant pathway in AML.
🔹 Lifestyle factors and treatment outcomes in colon cancer
Dr. En Cheng shares data from CALGB/SWOG 80702 showing that greater adherence to WCRF/AICR lifestyle recommendations at the start of adjuvant chemotherapy for stage III colon cancer was associated with better disease‑free survival and improved chemotherapy completion, without increased severe toxicity.
Together, these presentations reflect the breadth of Alliance research from improving how trials are designed, to uncovering biologic mechanisms that affect survival, to identifying modifiable factors that may enhance outcomes for patients already undergoing treatment.
We grateful to our investigators, collaborators and patient participants for continuing to push the field forward and for representing this work at . https://bit.ly/AACR-Alliance26

04/20/2026

🧡 April is Head and Neck Cancer Awareness Month 🧡
Cancers of the head and neck—including the mouth, throat, nasal cavity, and voice box—affect tens of thousands of people each year and can have a profound impact on speaking, swallowing, and quality of life. Yet these cancers often receive far less attention than others.
At the Alliance for Clinical Trials in Oncology, researchers are working to change that. Through a portfolio of active clinical trials, the Alliance is advancing new approaches to improve outcomes, reduce treatment side effects, and support patients and survivors living with head and neck cancers.
🔬 Current Alliance trials focus on:
• Improving pain control and reducing opioid use during treatment
• Testing innovative immunotherapy and targeted therapy combinations
• Exploring new options for patients with rare or hard to treat head and neck cancers
• Prioritizing survivorship and quality of life alongside disease control
💡 Why clinical trials matter:
Clinical trials are essential to moving care forward, offering patients access to promising new therapies while generating the evidence needed to shape tomorrow’s standards of care.
This Head and Neck Cancer Awareness Month, we’re proud to spotlight the investigators, advocates, and patients who are helping drive progress through research. We are also helping connect patients and providers with trials that may be right for them.
👉 Learn more about Alliance head and neck cancer trials: https://bit.ly/HN-2026

04/20/2026

🚨 Now Recruiting! 🚨
🩺 Dr. Brad McGregor the Dana-Farber Cancer Center leads the Alliance A032201 (STRIKE) trial to evaluate whether adding the anti-cancer drug tivozanib to standard immunotherapy after surgery can improve outcomes for patients with high-risk renal cell carcinoma.
This study aims to determine if combining targeted therapy with immunotherapy can reduce recurrence and advance personalized care.
📌 Learn more and share with your network: https://bit.ly/Alliance-A032201

04/17/2026

🔬 We were proud of the strong Alliance research at the 2026 AACR Annual Meeting, showcasing work that spans clinical trial methodology, cancer biology, and patient outcomes.
🔹 Advancing early‑phase trial design
Dr. Sumithra Mandrekar leads a methods workshop on model‑assisted designs for early‑phase clinical trials, highlighting how thoughtful statistical approaches can improve efficiency, rigor, and ethical standards—critical foundations for successful translational research.
🔹 New insights into AML disparities and survival
In work led by Dr. Ann‑Kathrin Eisfeld, researchers identified novel Rho‑GTPase regulatory protein (ARHG) gene family mutations that are more frequent in AML patients from diverse ancestral backgrounds and are associated with poorer survival. These findings help address gaps created by historically homogeneous genomic datasets and point toward a newly recognized, clinically relevant pathway in AML.
🔹 Lifestyle factors and treatment outcomes in colon cancer
Dr. En Cheng shares data from CALGB/SWOG 80702 showing that greater adherence to WCRF/AICR lifestyle recommendations at the start of adjuvant chemotherapy for stage III colon cancer was associated with better disease‑free survival and improved chemotherapy completion, without increased severe toxicity.
Together, these presentations reflect the breadth of Alliance research from improving how trials are designed, to uncovering biologic mechanisms that affect survival, to identifying modifiable factors that may enhance outcomes for patients already undergoing treatment.
We grateful to our investigators, collaborators and patient participants for continuing to push the field forward and for representing this work at .

04/17/2026

🔍 New Alliance Intervention Trial Now Enrolling
Drs. Rana McKay of UC San Diego Health and Misha Beltran of Dana-Farber Cancer Institute lead Alliance A032102:
👉 Can genetic testing help determine the best treatments for men with metastatic prostate cancer?
By personalizing therapy based on genetics, this trial aims to improve outcomes and quality of life for men with prostate cancer.
Learn more: https://bit.ly/Alliance-A032102

04/16/2026

For patients with early-stage triple-negative breast cancer who achieve a pathologic complete response after chemotherapy and pembrolizumab, what’s next? Should treatment continue—or is monitoring enough?
The Alliance A012103 trial, led by Dr. Sara Tolaney at the Dana-Farber Cancer Center, and is a phase III study designed to compare:
✅ Continuing pembrolizumab after surgery
✅ Monitoring only (“watch and wait”)
Why does this matter? If monitoring proves just as effective, patients could avoid unnecessary treatment, reduce side effects, and improve quality of life—while still maintaining excellent outcomes.
This research could reshape how we approach care for TNBC patients who respond well to initial therapy.
📌 Learn more or share with your network: https://bit.ly/Alliance-A012103

04/15/2026

New prostate cancer trial now enrolling! Thomas Hope, MD, of the University of California San Francisco and and Deaglan McHugh, MD, of Memorial Sloan Kettering Cancer Center lead Alliance A032304, a phase III study to optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in prostate cancer. Read the news release at https://bit.ly/AllianceA032304.

04/14/2026

🌟 New Trial for People Living with CLL/SLL 🌟
For people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),
a new clinical study (Alliance A042302) is exploring a targeted treatment approach using two cancer fighting pills — zanubrutinib and sonrotoclax.
🩺 Researchers hope this combo may help some patients reach a point where the cancer becomes undetectable, known as MRD negative — meaning you may be able to take a break from treatment for a while. 🎉Many people with CLL/SLL currently need ongoing treatments, which can be exhausting. This approach aims to give patients more freedom, fewer side effects, and more time to focus on life—not just cancer care. 💕
🔍 Dr. Jennifer R. Brown, the study chair from Dana-Farber Cancer Institute, says the new strategy has the potential to dramatically reduce the number of ongoing appointments, treatments, side effects and co-pays would give patients and their families much more freedom to enjoy their lives, despite a diagnosis of cancer.
👉Learn more at https://bit.ly/CLL-SLL

04/13/2026

💗 Advancing Quality of Life for Breast Cancer Survivors 💗
Breast cancer survivorship is about more than beating cancer—it’s about living well afterward. A new national clinical trial, REVITALIZE, led by the Alliance for Clinical Trials in Oncology and supported by the National Cancer Institute, is taking on a common but often overlooked long term side effect: chronic vaginal dryness caused by breast cancer treatments.
🔬 What the trial is studying:
REVITALIZE is a randomized, placebo controlled study testing whether vaginal fractional CO₂ laser therapy can safely relieve moderate to severe symptoms in breast cancer survivors—especially those who cannot use estrogen based treatments.
👩‍⚕️ Why it matters:
➡️ Symptoms can persist for years
➡️ They significantly affect comfort, intimacy, and overall well being
➡️ High quality clinical evidence in this area has been limited—until now
✨ As survival rates continue to rise, research like this reflects an important shift in oncology: prioritizing survivorship, supportive care, and patient reported outcomes with the same rigor as cancer treatment itself.
📣 Led by Maryam Lustberg, MD, of Yale University; Don Dizon, MD, of Tufts University; and Allison Quick, MD, of The Ohio State University, the REVITALIZE trial is now enrolling patients nationwide and represents a meaningful step toward improving long term quality of life for millions of women.
For more information, visit https://bit.ly/REVITALIZE2026.

Alliance for Clinical Trials in Oncology

04/22/2026

04/21/2026

04/21/2026

04/21/2026

04/20/2026

04/20/2026

04/17/2026

04/17/2026

04/16/2026

04/15/2026

04/14/2026

04/13/2026

Address

Opening Hours

Telephone

Website

Alerts

Shortcuts

Share

Category

Our Story

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm